Siltuximab (CNTO 328): a promising option for human malignancies
Authors:
Open Access
- 1 July 2015
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 9, 3455-3458
Abstract
Siltuximab (CNTO 328) is a promising antibody-drug conjugate targeting cytokine interleukin-6 (IL-6). It is highly binding to IL-6 and thus neutralizing IL-6 bioactivity and promoting death of tumor cell. In this review, we mainly focus on the mechanisms, clinical studies, and adverse effect of siltuximab in the treatment of human malignancies. We also provide our recommendations for siltuximab treatment in the future.Keywords
This publication has 39 references indexed in Scilit:
- Dose selection of siltuximab for multicentric Castleman’s diseaseCancer Chemotherapy and Pharmacology, 2015
- Siltuximab: A new option for the management of Castleman's diseaseDrugs of Today, 2015
- Exploiting interleukin 6 in multicentric Castleman's diseaseThe Lancet Oncology, 2014
- Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung CancerJournal of Thoracic Oncology, 2014
- Siltuximab in transplant-ineligible patients with myelomaThe Lancet Oncology, 2014
- Siltuximab: First Global ApprovalDrugs, 2014
- Antibodies to watch in 2014mAbs, 2014
- Paraneoplastic Thrombocytosis in Ovarian CancerNew England Journal of Medicine, 2012
- Interference of Monoclonal Antibody Therapies with Serum Protein Electrophoresis TestsClinical Chemistry, 2010
- Mcl-1 is Regulated by IL-6 and Mediates the Survival Activity of the Cytokine in a Model of Late Stage Prostate Carcinoma2008